Long-term randomized clinical trials of pharmacological treatment of obesity: Systematic review

Colombia Medica

Volumn 41, Issue 1, 2010, Pages 17-25

  Castañeda González, Lidia ^a   Camberos Solís, Rafael ^a   Bacardí Gascón, Montserrat ^a   Jiménez Cruz, Arturo ^a  

^a UNIVERSIDAD AUTÓNOMA DE BAJA CALIFORNIA   (Mexico)

Author keywords

Obesity; Orlistat; Pharmacotherapy; Rimonabant; Sibutramine

Indexed keywords

PLACEBO; RIMONABANT; SIBUTRAMINE; TETRAHYDROLIPSTATIN;

ABDOMINAL PAIN; ANXIETY; ARTHRALGIA; ARTICLE; ASTHENIA; BACKACHE; BODY MASS; CLINICAL TRIAL; CONSTIPATION; DEFECATION HABIT; DEPRESSION; DIARRHEA; DIZZINESS; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; FECES INCONTINENCE; FLATULENCE; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HEADACHE; HEALTH CARE COST; HEALTH SERVICE; HUMAN; HYPERTENSION; INCREASED APPETITE; INFLUENZA; INSOMNIA; LIFESTYLE MODIFICATION; LOW CALORY DIET; MEXICO; MORBIDITY; MORTALITY; NAUSEA; NUTRITIONAL SUPPORT; OBESITY; PATIENT CARE; PATIENT MONITORING; PHARYNGITIS; PRESCRIPTION; RASH; RHINOPHARYNGITIS; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT PLANNING; UPPER RESPIRATORY TRACT INFECTION; VIRAL GASTROENTERITIS; WEIGHT GAIN; WEIGHT REDUCTION; XEROSTOMIA;

EID: 77950414924     PISSN: 16579534     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Jiménez-Cruz A, Bacardi-Gascón M. The fattening burden of type 2 diabetes on Mexicans. Diabetes Care. 2004; 27: 1213-1215
2. Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults 1999-2000. JAMA. 2002; 288: 1723-1727
3. Ruiz AL, Castillo M, Orea A, Mejía S, Miguel A. Prevalence of self-reported overweight-obesity and its association with socioeconomic and health factors among older Mexican adults. Salud Pub Mex. 2007; 49: S482-7.
4. Hitchcock PN, Pugh JA. Management of overweight and obese adults. BMJ. 2002; 325: 757-761
5. Glazer G. Long-term pharmacotherapy of obesity 2000: a review of efficacy and safety. Arch Intern Med. 2001; 161: 1814-1824
6. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1year experience from the RIO-Europe study. Lancet. 2005; 365: 1389-1397.
7. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996; 17: 1-12.
8. Davidson MH, Haupman J, DiGirolamo, Foreyt JP, Halsted CH, Heber D, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized control trial. JAMA. 1999; 281: 235-242
9. Karhunen L, Franssila-Kallunki A, Rissanen P, Valve R, Kolehmainen M, Rissanen A, et al. Effect of orlistat treatment on body composition and resting energy expenditure during a two-year weight-reduction programme in obese Finns. Int J Obes. 2000; 24: 1567-1572
10. Hauptman J, Lucas C, Boldrin MN, Collins H, Segal KR. Orlistat in the long-term treatment of obesity in the primary care settings. Arch Fam Med. 2000; 9: 160-167
11. Rossner S, Sjostrom L, Noack R, Meiders E, Noseda G. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. Obes Res. 2000; 8: 49-61.
12. Torgerson JS, Hauptman J, Noack R, Boldrin MN, Sjostrom L. Xenical in the prevention of diabetes in obese subjects (xendos) study. Diabetes Care. 2004; 27: 155-161
13. O'Brien P, Dixon JB, Laurie C, Skinner S, Proletto J, Mcneil J, et al. Treatment of mild to moderate obesity with laparoscopic adjustable gastric banding or an intensive medical program. Ann Inter Med. 2006; 144: 625-633
14. Richelsen B, Tonstad S, Rossner S, Toubro S, Niskanen L, Madsbad S, et al. Effect of orlistat on weight regain and cardiovascular risk factors following a very-low-energy diet in abdominally obese patients. Diabetes Care. 2007; 30: 27-32.
15. James WPT, Astrup A, Finer N, Hilsted J, Kopelman P, Rossner S, et al. Effect of sibutramine of weight maintenance after weight loss: a randomized trial. Lancet. 2000; 356: 2119-2125
16. Redmon JB, Reck KP, Raatz SK, Swanson JE, Kwong CA, Ji H, et al. Two-year outcome of a combination of weight loss therapies for type 2 diabetes. Diabetes Care. 2005; 28: 1311-1315
17. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients RIO-north America: a randomized controlled trial. JAMA. 2006; 295: 761-775
18. 1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe study. Eur Heart J. 2008; 29: 1761-1771
19. Diario oficial de la Federación. Secretaría de Gobernación, México 2008. Fecha de acceso 30 de abril, 2008. Disponible en: http //www.sat.gob.mx/sitio-internet/asistencia- contribuyente/informacion-frecuente/salarios-minimos
20. Márquez-Ibañez B, Armendariz-Anguiano AL, Bacardí-Gascón M, Jiménez Cruz A. Revisión de ensayos clínicos controlados mediante cambios en el comportamiento para el tratamiento de la obesidad. Nutr Hosp. 2008; 28: 1-5.